29 46

Cited 0 times in

Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study

 Minkyung Han  ;  Yoon Suk Jung  ;  Jae Hee Cheon  ;  Sohee Park 
 YONSEI MEDICAL JOURNAL, Vol.61(5) : 382-390, 2020-05 
Journal Title
Issue Date
Adalimumab / therapeutic use ; Adult ; Antibodies, Monoclonal / therapeutic use ; Colitis, Ulcerative / drug therapy* ; Female ; Humans ; Infliximab / therapeutic use ; Kaplan-Meier Estimate ; Male ; Proportional Hazards Models ; Regression Analysis ; Time Factors ; Treatment Outcome ; Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Ulcerative colitis ; anti-TNF ; clinical outcome ; early use
Purpose: The optimal timing of anti-tumor necrosis factor (anti-TNF) initiation in patients with ulcerative colitis (UC) remains unclear. Very little is known about the clinical outcomes after the early versus late initiation of anti-TNF therapy, especially in Asian UC patients. Here we aimed to assess whether earlier anti-TNF treatment initiation results in favorable clinical outcomes in Korean UC patients. Materials and methods: Using the Korean National Health Insurance claims database, we studied patients who were diagnosed with UC and received anti-TNF therapy for more than 6 months between 2010 and 2016. Using a Cox proportional hazard model, clinical outcomes including colectomy, UC-related emergency room (ER) visits, UC-related hospitalizations, and the need for corticosteroids were compared between early (≤2 years of diagnosis) and late (>2 years of diagnosis) initiators of anti-TNF therapy. Results: Among 17167 UC patients, 698 patients who received anti-TNF therapy for more than 6 months were included (420 infliximab, 242 adalimumab, and 36 golimumab). Of the 698 patients, 299 (42.8%) initiated anti-TNF therapy within 2 years of diagnosis. There were no significant differences in the risk of colectomy [adjusted hazard ratio (aHR), 0.41; 95% confidence interval (CI), 0.04-3.90], ER visits (aHR, 0.98; 95% CI, 0.50-1.92), hospitalization (aHR, 0.76; 95% CI, 0.57-1.01), and corticosteroid use (aHR, 1.04; 95% CI, 0.71-1.50) between early and late initiators of anti-TNF therapy. Conclusion: Patients receiving early anti-TNF therapy had similar clinical outcomes to those of late initiators, suggesting that early anti-TNF therapy initiation offers little benefit in patients with UC.
Files in This Item:
T202003313.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
4. Graduate School of Public Health (보건대학원) > Graduate School of Public Health (보건대학원) > 1. Journal Papers
Yonsei Authors
Park, So Hee(박소희) ORCID logo https://orcid.org/0000-0001-8513-5163
Cheon, Jae Hee(천재희) ORCID logo https://orcid.org/0000-0002-2282-8904
Han, Minkyung(한민경) ORCID logo https://orcid.org/0000-0002-5011-5557
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.